Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7L211

UPID:
ABHDD_HUMAN

ALTERNATIVE NAMES:
Alpha/beta hydrolase domain-containing protein 13

ALTERNATIVE UPACC:
Q7L211; B3KWE7; Q8NBW1; Q96JX9

BACKGROUND:
The Alpha/beta hydrolase domain-containing protein 13, known as Protein ABHD13, is integral to a wide range of biological processes. Despite the lack of detailed information on its specific roles, ABHD13's ubiquitous expression indicates its importance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein ABHD13 holds promise for uncovering novel therapeutic approaches. As research progresses, the potential for ABHD13 to become a target in disease intervention strategies becomes increasingly plausible, highlighting the need for further investigation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.